Corneal Cross-Linking with Selective Epithelial Disruption

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing cross-linking treatments for the eye, such as those for keratoconus and post-LASIK ectasia, face challenges in efficiently delivering cross-linking agents and photoactivating light to the cornea, particularly due to the impermeability of the corneal epithelium and the need for precise control over cross-linking depth and distribution.

Innovation Solution

The system employs a laser system or mechanical disruptor to ablate the apical layers of the corneal epithelium, allowing for enhanced permeability and precise delivery of cross-linking agents, combined with controlled photoactivating light to achieve targeted cross-linking, using systems like excimer or femtosecond lasers and optical elements for precise light focusing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If the corneal epithelium is left intact, then the cornea is protected from infection and damage, but the cross-linking agent cannot penetrate the cornea effectively

Engineering Contradiction:
Improvecorneal protectionVSAvoidcross-linking agent penetration
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The corneal epithelium is disrupted prior to application of the cross-linking agent, creating enhanced permeability pathways. This preliminary disruption allows the cross-linking agent to penetrate effectively while the epithelium remains in place, resolving the contradiction between maintaining protective integrity and enabling drug delivery.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If the cross-linking treatment is applied to the entire cornea, then comprehensive stabilization is achieved, but treatment time and patient discomfort increase

Engineering Contradiction:
Improvecorneal stabilizationVSAvoidtreatment duration
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The disruption and cross-linking treatment are applied selectively to specific regions of the cornea rather than uniformly across the entire surface. This localized approach concentrates the therapeutic effect on areas requiring stabilization while reducing overall treatment time and patient discomfort.

Inventive Principle:
Principle #3Local quality

3Quantity of substance

If deeper tissue disruption is performed to enhance agent delivery, then cross-linking agent penetration improves, but tissue damage and infection risk increase

Engineering Contradiction:
Improvecross-linking agent penetrationVSAvoidtissue damage
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The disruption is applied to a controlled extent - sufficient to enhance permeability but limited to avoid excessive tissue damage. The disruption depth and intensity are carefully calibrated to achieve the minimum necessary penetration enhancement while maintaining tissue integrity and minimizing infection risk.

Inventive Principle:
Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the efficiency and precision of cross-linking treatments, reducing treatment time, minimizing patient discomfort, and reducing risks of infection and tissue damage, while achieving desired refractive corrections and corneal stabilization.

Implementation Method 1

a laser system configured to direct an ablative laser to a cornea of an eye... control the laser system to ablate tissue at an area at a surface of the cornea

Methodology Applied
Scientific EffectLaser ablation: Laser Ablation

Implementation Method 2

deliver photoactivating light to the cornea... activates the cross-linking agent to generate cross-linking activity in the cornea

Methodology Applied
Scientific EffectPhotoactivation: Photo-oxidation

Data Source

PatentEP3827793B1Systems for cross-linking treatments of an eye
Publication Date: 2026.04.08 AVEDRO INC
  • EP3827793B1 patent drawingFigure 1
  • EP3827793B1 patent drawingFigure 2A
  • EP3827793B1 patent drawingFigure 2B

AI summary

Example eye treatments determine an area at a surface of a cornea for delivery of a cross-linking agent. The example treatments disrupt tissue at the area at the surface of the cornea up to a depth corresponding to apical layers of superficial squamous cells of the cornea, e.g., no greater than approximately 10 µm to approximately 15 µm. The example treatments apply a cross-linking agent to the area at the surface of the cornea. The cross-linking agent is transmitted through the disrupted area at a greater rate relative to non-disrupted areas of the cornea. The example treatments deliver photoactivating light to the cornea. The photoactivating light activates the cross-linking agent to generate cross-linking activity in the cornea.